|
1
|
Guglielmi A, Ruzzenente A, Campagnaro T,
Pachera S, Valdegamberi A, Nicoli P, Cappellani A, Malfermoni G and
Iacono C: Intrahepatic cholangiocarcinoma: Prognostic factors after
surgical resection. World J Surg. 33:1247–1254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson CD, Pinson CW, Berlin J and Chari
RS: Diagnosis and treatment of cholangiocarcinoma. Oncologist.
9:43–57. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vilana R, Forner A, Bianchi L,
García-Criado A, Rimola J, de Lope CR, Reig M, Ayuso C, Brú C and
Bruix J: Intrahepatic peripheral cholangiocarcinoma in cirrhosis
patients may display a vascular pattern similar to hepatocellular
carcinoma on contrast-enhanced ultrasound. Hepatology.
51:2020–2029. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khan SA, Thomas HC, Davidson BR and
Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khan SA, Davidson BR, Goldin R, Pereira
SP, Rosenberg WM, Taylor-Robinson SD, Thillainayagam AV, Thomas HC,
Thursz MR and Wasan H: British Society of Gastroenterology:
Guidelines for the diagnosis and treatment of cholangiocarcinoma:
Consensus document. Gut. 51:(Suppl 6). VI1–VI9. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Isa T, Tomita S, Nakachi A, Miyazato H,
Shimoji H, Kusano T, Muto Y and Furukawa M: Analysis of
microsatellite instability, K-ras gene mutation and p53 protein
overexpression in intrahepatic cholangiocarcinoma.
Hepatogastroenterology. 49:604–608. 2002.PubMed/NCBI
|
|
7
|
Weber J, Ollinger R, Friedrich M, Ehmer U,
Barenboim M, Steiger K, Heid I, Mueller S, Maresch R, Engleitner T,
et al: CRISPR/Cas9 somatic multiplex-mutagenesis for
high-throughput functional cancer genomics in mice. Proc Natl Acad
Sci USA. 112:13982–13987. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lee H, Wang K, Johnson A, Jones DM, Ali
SM, Elvin JA, Yelensky R, Lipson D, Miller VA, Stephens PJ, et al:
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma
reveals a long tail of therapeutic targets. J Clin Pathol.
69:403–408. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang SH, Lin HY, Changou CA, Chen CH, Liu
YR, Wang J, Jiang X, Luh F and Yen Y: Integrin β3 and LKB1 are
independently involved in the inhibition of proliferation by
lovastatin in human intrahepatic cholangiocarcinoma. Oncotarget.
7:362–373. 2016.PubMed/NCBI
|
|
10
|
Tepsiri N, Chaturat L, Sripa B, Namwat W,
Wongkham S, Bhudhisawasdi V and Tassaneeyakul W: Drug sensitivity
and drug resistance profiles of human intrahepatic
cholangiocarcinoma cell lines. World J Gastroenterol. 11:2748–2753.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang MY, Li SH, Huang GL, Lin GH, Shuang
ZY, Lao XM, Xu L, Lin XJ, Wang HY and Li SP: Identification of a
novel microRNA signature associated with intrahepatic
cholangiocarcinoma (ICC) patient prognosis. BMC Cancer. 15:642015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang J, Xie H, Ling Q, Lu D, Lv Z, Zhuang
R, Liu Z, Wei X, Zhou L, Xu X and Zheng S: Coding-noncoding gene
expression in intrahepatic cholangiocarcinoma. Transl Res.
168:107–121. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu YF, Ge FJ, Han B, Yang XQ, Su H, Zhao
AC, Zhao MH, Yang YB and Yang J: High-mobility group box 1
expression and lymph node metastasis in intrahepatic
cholangiocarcinoma. World J Gastroenterol. 21:3256–3265.
2015.PubMed/NCBI
|
|
14
|
Oishi N, Kumar MR, Roessler S, Ji J,
Forgues M, Budhu A, Zhao X, Andersen JB, Ye QH, Jia HL, et al:
Transcriptomic profiling reveals hepatic stem-like gene signatures
and interplay of miR-200c and epithelial-mesenchymal transition in
intrahepatic cholangiocarcinoma. Hepatology. 56:1792–1803. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Waggott D, Chu K, Yin S, Wouters BG, Liu
FF and Boutros PC: NanoStringNorm: An extensible R package for the
pre-processing of NanoString mRNA and miRNA data. Bioinformatics.
28:1546–1548. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Graveley BR: Alternative splicing:
Increasing diversity in the proteomic world. Trends Genet.
17:100–107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cieply B and Carstens RP: Functional roles
of alternative splicing factors in human disease. Wiley Interdiscip
Rev RNA. 6:311–326. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Emig D, Salomonis N, Baumbach J, Lengauer
T, Conklin BR and Albrecht M: AltAnalyze and DomainGraph: Analyzing
and visualizing exon expression data. Nucleic Acids Res.
38:W755–W762. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for Annotation,
Visualization, and Integrated Discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
21
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pradervand S, Paillusson A, Thomas J,
Weber J, Wirapati P, Hagenbüchle O and Harshman K: Affymetrix
Whole-Transcript Human Gene 1.0 ST array is highly concordant with
standard 3′ expression arrays. Biotechniques. 44:759–762. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sawai H, Okada Y, Funahashi H, Matsuo Y,
Takahashi H, Takeyama H and Manabe T: Activation of focal adhesion
kinase enhances the adhesion and invasion of pancreatic cancer
cells via extracellular signal-regulated kinase-1/2 signaling
pathway activation. Mol Cancer. 4:372005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee JI and Campbell JS: Role of
desmoplasia in cholangiocarcinoma and hepatocellular carcinoma. J
Hepatol. 61:432–434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Utispan K, Thuwajit P, Abiko Y, Charngkaew
K, Paupairoj A, Chau-in S and Thuwajit C: Gene expression profiling
of cholangiocarcinoma-derived fibroblast reveals alterations
related to tumor progression and indicates periostin as a poor
prognostic marker. Mol Cancer. 9:132010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soejima Y, Inoue M, Takahashi Y, Uozaki H,
Sawabe M and Fukusato T: Integrins αvβ6, α6β4 and α3β1 are
down-regulated in cholangiolocellular carcinoma but not
cholangiocarcinoma. Hepatol Res. 44:E320–E334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun B, Xie C, Zheng T, Yin D, Wang J,
Liang Y, Li Y, Yang G, Shi H, Pei T, et al: Selecting molecular
therapeutic drug targets based on the expression profiles of
intrahepatic cholangiocarcinomas and miRNA-mRNA regulatory
networks. Oncol Rep. 35:382–390. 2016.PubMed/NCBI
|
|
30
|
Deng G, Teng Y, Huang F, Nie W, Zhu L,
Huang W and Xu H: MicroRNA-101 inhibits the migration and invasion
of intrahepatic cholangiocarcinoma cells via direct suppression of
vascular endothelial growth factor-C. Mol Med Rep. 12:7079–7085.
2015.PubMed/NCBI
|
|
31
|
Xiong X, Sun D, Chai H, Shan W, Yu Y, Pu L
and Cheng F: MiR-145 functions as a tumor suppressor targeting
NUAK1 in human intrahepatic cholangiocarcinoma. Biochem Biophys Res
Commun. 465:262–269. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Collins AL, Wojcik S, Liu J, Frankel WL,
Alder H, Yu L, Schmittgen TD, Croce CM and Bloomston M: A
differential microRNA profile distinguishes cholangiocarcinoma from
pancreatic adenocarcinoma. Ann Surg Oncol. 21:133–138. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Papaconstantinou I, Karakatsanis A,
Gazouli M, Polymeneas G and Voros D: The role of microRNAs in liver
cancer. Eur J Gastroenterol Hepatol. 24:223–228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ura K, Obama K, Satoh S, Sakai Y, Nakamura
Y and Furukawa Y: Enhanced RASGEF1A expression is involved in the
growth and migration of intrahepatic cholangiocarcinoma. Clin
Cancer Res. 12:6611–6616. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chang CC, Lin CC, Hsieh WL, Lai HW, Tsai
CH and Cheng YW: MicroRNA expression profiling in PBMCs: A
potential diagnostic biomarker of chronic hepatitis C. Dis Markers.
2014:3671572014. View Article : Google Scholar : PubMed/NCBI
|
